2 weeks Ago By gullapalli
has announced the issuance of US Patent No. 12,134,635 covering its two new drug candidates, SON-1411 and SON-1400, expected to advance treatment options for cancer. The patent, titled ‘Interleukin 18 (IL-18) Variants and Fusion Proteins Comprising Same’ was issued by the US Patent and Trademark Office.
The gold standard of business intelligence. The drug candidates comprise modified versions of recombinant human interleukin-18 with the patent effective till June 2044. SON-1411 is a bifunctional fusion protein that combines IL-18 with single-chain wild-type IL-12, connected to the company’s Fully Human Albumin Binding (FHAB) platform.
Another drug, SON-1400 is a monofunctional fusion protein comprising the FHAB-connected IL-18 domain. Sonnet founder and CEO Pankaj Mohan said: “The issuance of this intellectual property is an important milestone that we believe provides significant differentiation from competitors trying to tap the full biological potential of IL-18, either alone or in combination with IL-12. Access the most comprehensive Company Profiles on the market, powered by GlobalData.
Save hours of research. Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles.
However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form “IL-18 is a key cytokine that, when combined synergistically with IL-12, has the potential to be an important therapeutic asset for oncology and cell-based therapy.” The company’s FHAB platform aims to target tumour and lymphatic tissue, improving the efficacy and safety of immune-modulating biologic drugs. It also prolongs the biological activity of connected molecules by attaching native albumin in the serum aiming the microenvironment of the tumour via high-affinity binding to glycoprotein 60 and the Secreted Protein Acidic and Rich in Cysteine.
IL-18 plays a prominent role in regulating adaptive and innate immune responses, affecting natural killer cells, monocytes and other cell types. IL-18BP acts as a decoy receptor, hindering IL-18-mediated tumour-infiltrating lymphocyte activation. The company is developing bifunctional cytokine molecules, IL-18-FHAB-IL12 and IL-18-FHAB.
These molecules have an IL-18 domain that does not bind IL-18BP but maintains full IL-18 and IL-12 bioactivity. This development could potentially expand immunotherapy applications for patients with cancer..
